APA (7th ed.) Citation

Dominguez-Mozo, M. I., Galán, V., Ramió-Torrentà, L., Quiroga, A., Quintana, E., Villar, L. M., . . . Alvarez-Lafuente, R. (2024). A two-years real-word study with fingolimod: Early predictors of efficacy and an association between EBNA-1 IgG titers and multiple sclerosis progression. Frontiers in immunology, 15, 1384411. https://doi.org/10.3389/fimmu.2024.1384411

Chicago Style (17th ed.) Citation

Dominguez-Mozo, Maria Inmaculada, et al. "A Two-years Real-word Study with Fingolimod: Early Predictors of Efficacy and an Association Between EBNA-1 IgG Titers and Multiple Sclerosis Progression." Frontiers in Immunology 15 (2024): 1384411. https://doi.org/10.3389/fimmu.2024.1384411.

MLA (9th ed.) Citation

Dominguez-Mozo, Maria Inmaculada, et al. "A Two-years Real-word Study with Fingolimod: Early Predictors of Efficacy and an Association Between EBNA-1 IgG Titers and Multiple Sclerosis Progression." Frontiers in Immunology, vol. 15, 2024, p. 1384411, https://doi.org/10.3389/fimmu.2024.1384411.